サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1219629

気管支拡張薬の世界市場規模、シェア、産業動向分析レポート：薬物クラス別、投与経路別、疾患別（喘息、慢性閉塞性肺疾患（COPD）、その他）、地域別展望・予測、2022～2028年版

Global Bronchodilators Market Size, Share & Industry Trends Analysis Report By Drug Class, By Route of Administration, By Disease (Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Regional Outlook and Forecast, 2022 - 2028
出版日: | 発行: KBV Research | ページ情報: 英文 203 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
気管支拡張薬の世界市場規模、シェア、産業動向分析レポート：薬物クラス別、投与経路別、疾患別（喘息、慢性閉塞性肺疾患（COPD）、その他）、地域別展望・予測、2022～2028年版
出版日: 2023年01月31日
発行: KBV Research
ページ情報: 英文 203 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

気管支拡張薬の世界市場規模は、予測期間中にCAGR3.9％で成長し、2028年には270億米ドルに達すると予測されます。

β2アゴニストは、COPDと喘息の両方に利用されますが、一部のβ2アゴニストはCOPDの患者にのみ推奨されています。一般的には、小型のハンドヘルド吸入器の助けを借りて吸入しますが、シロップや錠剤としても販売されています。また、症状が急な場合や重い場合は、体内に注射したり、ネブライザーを使用することもあります。ネブライザーは、液体の薬を細かい霧状にする圧縮機です。ベータ2作動薬は、気道にある筋肉のベータ2受容体として知られる受容体を刺激することにより、筋肉を弛緩させ、気道を拡張させる働きをします。

抗コリン薬は、抗ムスカリン薬としても知られており、主にCOPDの治療に使用されますが、場合によっては、喘息の治療にも使用されます。彼らは、吸入器の助けを借りて撮影しますが、ネブライジング薬は、突然の必要性を利用できます。抗コリン薬は、コリン作動性神経をブロックすることによって、気道を拡張させます。これらの神経は、気道を裏打ちする筋肉を締め付けることを強制することができる化学物質を放出します。テオフィリンは一般にカプセルまたは錠剤の形で服用しますが、症状がひどい場合は、アミノフィリンと呼ばれる別のバージョンを静脈に直接投与することができます。

COVID-19の影響分析

COVID-19は、COPDや喘息の患者を重要視しているため、多くの国がCOPDや喘息の治療を拒否し、ロックダウンしたため、気管支拡張剤市場に初期段階から影響を及ぼしています。なぜなら、サプライチェーンの停止のために、気管支拡張薬の不足があっています。気管支拡張剤製造会社の多くが、パンデミックと人手不足のために生産停止を余儀なくされました。さらに、政府の新たな規制により事業活動が停止し、気管支拡張剤市場における企業の収益に直接的な影響を及ぼしました。

市場成長要因

世界の大気汚染の増加

自動車、家庭での燃焼、森林火災、工業施設は、身近な大気汚染源です。公衆衛生上の主要な懸念となる汚染物質には、粒子状物質、一酸化炭素、オゾン、二酸化硫黄、窒素が含まれます。屋内および屋外の大気汚染は、呼吸器疾患などの原因となり、死亡率や罹患率の大きな要因となっています。世界保健機関（WHO）によると、世界人口のほぼ全員がWHOガイドラインの制限値を超え、汚染物質が多い空気を吸っています。その中でも、低・中所得国が最も高い曝露量に苦しんでいます。

急増する老年人口

WHOによると、2030年には世界の6人に1人が60歳以上の高齢者になると言われています。世界の60歳以上人口に占める割合は、2020年の10億人から14億人に増加します。2020年から2050年にかけて、世界の60歳以上人口は約21億人に倍増し、80歳は4億2600万人に3倍増します。一国の人口分布が高齢者にシフトすることは、人口高齢化と呼ばれ、高所得国ではすでに始まっていますが、現在、低・中所得国で最も大きな変化が起きています。2050年には、世界人口の3分の2が60歳以上の低・中所得国になると言われています。

市場抑制要因

画像診断機器の高コスト

胸部X線検査は、多くの肺疾患の診断に役立ち、息切れの他の原因を除外することができます。発展途上国のさまざまな病院では、高額な費用と財政的な制約のため、画像診断機器に投資することができません。特に低所得国では診断の需要が高いため、最新の画像診断装置を購入できない多くの病院は、代わりに再建された画像診断装置を利用することを選択します。

薬物クラスの展望

気管支拡張剤市場は、薬物クラスにより、β-アドレナリン系、キサンチン誘導体、抗コリン系に分類されます。抗コリン作動性セグメントは、2021年の気管支拡張剤市場において有望な成長率を獲得しました。これは、短時間作用型および長時間作用型の製剤で抗コリン剤が利用可能であることによります。これらの薬剤は、気道の収縮による副交感神経の反射を防ぎ、気道を開いたままにすることができます。

投与経路の展望

気管支拡張剤市場は、投与経路によって経口剤、鼻腔剤（吸入剤）、注射剤に分類されます。経口セグメントは、2021年の気管支拡張剤市場において突出した収益シェアを調達しました。これは、多くの患者や臨床医が注射剤投与の副作用を避けることを好むためです。また、多くのジェネリック代替品よりもコストが低く、非侵襲性、薬剤投与の利便性、患者のコンプライアンスなど、多くの利点があります。

疾患別の展望

気管支拡張剤市場は、疾患別に喘息、慢性閉塞性肺疾患（COPD）、その他に分類されます。喘息分野は、2021年の気管支拡張剤市場で最大の収益シェアを示しました。これは、人口の間で喘息の有病率が上昇していることに起因しています。また、多くの中・後期開発機関が存在し、研究開発のパイプラインが充実しています。

地域別の展望

地域別では、気管支拡張剤市場は北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2021年の気管支拡張剤市場において最も高い収益シェアを獲得しています。この成長は、即効性と高効率の薬剤に対する需要の増加によるものです。COPD患者の急増は、大気汚染、粉塵、化学物質を扱う作業、小児肺感染症の既往、受動喫煙が原因です。また、喫煙者の多さにも起因しています。大気汚染、喫煙者数の多さ、老齢者の増加などが、この地域の気管支拡張剤市場の成長を押し上げると予想されます。

目次

第1章 市場の範囲と調査手法

  • 市場の定義
  • 目的
  • 市場規模
  • セグメンテーション
    • 気管支拡張薬の世界市場、薬物クラス別
    • 気管支拡張薬の世界市場、投与経路別
    • 気管支拡張薬の世界市場、疾患別
    • 気管支拡張薬の世界市場、地域別
  • 調査手法

第2章 市場概要

  • イントロダクション
    • 概要説明
      • 市場の構成とシナリオ
  • 市場に影響を与える主な要因
    • 市場促進要因
    • 市場の抑制要因

第3章 気管支拡張薬の世界市場：薬物クラス別

  • β-アドレナリンの世界市場：地域別
  • キサンチン誘導体の世界市場：地域別
  • 抗コリン作用の世界市場：地域別

第4章 気管支拡張薬の世界市場：投与経路別

  • 鼻腔用（吸入用）の世界市場：地域別
  • 経口剤の世界市場：地域別
  • 注射剤の世界市場：地域別

第5章 気管支拡張薬の世界市場：疾患別

  • 喘息の世界市場：地域別
  • 慢性閉塞性肺疾患（COPD）の世界市場：地域別
  • その他の世界市場：地域別

第6章 気管支拡張薬の世界市場：地域別地域別市場

  • 北米
    • 気管支拡張薬の北米市場：国別内訳
      • 米国
      • カナダ
      • メキシコ
      • その他北米地域
  • 欧州
    • 欧州気管支拡張剤国別市場
      • ドイツ
      • 英国
      • フランス
      • ロシア
      • スペイン
      • イタリア
      • その他欧州
  • アジア太平洋地域
    • アジア太平洋地域の気管支拡張薬の国別市場
      • 中国
      • 日本
      • インド
      • 韓国
      • シンガポール
      • マレーシア
      • その他アジア太平洋地域
  • LAMEA
    • LAMEAの気管支拡張剤市場：国別
      • ブラジル
      • アルゼンチン
      • UAE
      • サウジアラビア
      • 南アフリカ
      • ナイジェリア
      • その他のLAMEA

第7章 企業プロファイル

  • Glenmark Pharmaceuticals Limited
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Limited
  • Viatris, Inc.（Mylan N.V.）
  • Novartis AG
  • Boehringer Ingelheim International Gmbh
  • Sun Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • TABLE 1 Global Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 2 Global Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 3 Global Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 4 Global Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 5 Global Beta-Adrenergic Market by Region, 2018 - 2021, USD Million
  • TABLE 6 Global Beta-Adrenergic Market by Region, 2022 - 2028, USD Million
  • TABLE 7 Global Xanthine Derivatives Market by Region, 2018 - 2021, USD Million
  • TABLE 8 Global Xanthine Derivatives Market by Region, 2022 - 2028, USD Million
  • TABLE 9 Global Anticholinergic Market by Region, 2018 - 2021, USD Million
  • TABLE 10 Global Anticholinergic Market by Region, 2022 - 2028, USD Million
  • TABLE 11 Global Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 12 Global Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 13 Global Nasal (Inhalable) Market by Region, 2018 - 2021, USD Million
  • TABLE 14 Global Nasal (Inhalable) Market by Region, 2022 - 2028, USD Million
  • TABLE 15 Global Oral Market by Region, 2018 - 2021, USD Million
  • TABLE 16 Global Oral Market by Region, 2022 - 2028, USD Million
  • TABLE 17 Global Injectable Market by Region, 2018 - 2021, USD Million
  • TABLE 18 Global Injectable Market by Region, 2022 - 2028, USD Million
  • TABLE 19 Global Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 20 Global Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 21 Global Asthma Market by Region, 2018 - 2021, USD Million
  • TABLE 22 Global Asthma Market by Region, 2022 - 2028, USD Million
  • TABLE 23 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region, 2018 - 2021, USD Million
  • TABLE 24 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region, 2022 - 2028, USD Million
  • TABLE 25 Global Others Market by Region, 2018 - 2021, USD Million
  • TABLE 26 Global Others Market by Region, 2022 - 2028, USD Million
  • TABLE 27 Global Bronchodilators Market by Region, 2018 - 2021, USD Million
  • TABLE 28 Global Bronchodilators Market by Region, 2022 - 2028, USD Million
  • TABLE 29 North America Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 30 North America Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 31 North America Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 32 North America Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 33 North America Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 34 North America Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 35 North America Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 36 North America Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 37 North America Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 38 North America Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 39 North America Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 40 North America Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 41 North America Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 42 North America Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 43 North America Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 44 North America Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 45 North America Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 46 North America Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 47 North America Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 48 North America Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 49 North America Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 50 North America Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 51 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 52 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 53 North America Others Market by Country, 2018 - 2021, USD Million
  • TABLE 54 North America Others Market by Country, 2022 - 2028, USD Million
  • TABLE 55 North America Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 56 North America Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 57 US Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 58 US Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 59 US Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 60 US Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 61 US Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 62 US Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 63 US Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 64 US Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 65 Canada Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 66 Canada Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 67 Canada Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 68 Canada Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 69 Canada Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 70 Canada Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 71 Canada Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 72 Canada Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 73 Mexico Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 74 Mexico Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 75 Mexico Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 76 Mexico Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 77 Mexico Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 78 Mexico Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 79 Mexico Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 80 Mexico Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 81 Rest of North America Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 82 Rest of North America Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 83 Rest of North America Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 84 Rest of North America Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 85 Rest of North America Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 86 Rest of North America Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 87 Rest of North America Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 88 Rest of North America Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 89 Europe Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 90 Europe Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 91 Europe Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 92 Europe Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 93 Europe Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 94 Europe Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 95 Europe Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 96 Europe Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 97 Europe Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 98 Europe Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 99 Europe Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 100 Europe Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 101 Europe Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 102 Europe Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 103 Europe Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 104 Europe Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 105 Europe Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 106 Europe Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 107 Europe Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 108 Europe Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 109 Europe Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 110 Europe Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 111 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 112 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 113 Europe Others Market by Country, 2018 - 2021, USD Million
  • TABLE 114 Europe Others Market by Country, 2022 - 2028, USD Million
  • TABLE 115 Europe Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 116 Europe Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 117 Germany Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 118 Germany Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 119 Germany Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 120 Germany Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 121 Germany Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 122 Germany Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 123 Germany Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 124 Germany Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 125 UK Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 126 UK Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 127 UK Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 128 UK Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 129 UK Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 130 UK Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 131 UK Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 132 UK Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 133 France Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 134 France Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 135 France Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 136 France Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 137 France Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 138 France Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 139 France Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 140 France Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 141 Russia Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 142 Russia Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 143 Russia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 144 Russia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 145 Russia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 146 Russia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 147 Russia Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 148 Russia Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 149 Spain Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 150 Spain Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 151 Spain Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 152 Spain Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 153 Spain Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 154 Spain Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 155 Spain Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 156 Spain Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 157 Italy Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 158 Italy Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 159 Italy Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 160 Italy Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 161 Italy Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 162 Italy Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 163 Italy Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 164 Italy Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 165 Rest of Europe Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 166 Rest of Europe Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 167 Rest of Europe Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 168 Rest of Europe Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 169 Rest of Europe Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 170 Rest of Europe Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 171 Rest of Europe Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 172 Rest of Europe Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 173 Asia Pacific Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 174 Asia Pacific Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 175 Asia Pacific Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 176 Asia Pacific Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 177 Asia Pacific Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 178 Asia Pacific Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 179 Asia Pacific Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 180 Asia Pacific Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 181 Asia Pacific Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 182 Asia Pacific Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 183 Asia Pacific Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 184 Asia Pacific Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 185 Asia Pacific Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 186 Asia Pacific Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 187 Asia Pacific Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 188 Asia Pacific Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 189 Asia Pacific Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 190 Asia Pacific Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 191 Asia Pacific Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 192 Asia Pacific Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 193 Asia Pacific Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 194 Asia Pacific Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 195 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 196 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 197 Asia Pacific Others Market by Country, 2018 - 2021, USD Million
  • TABLE 198 Asia Pacific Others Market by Country, 2022 - 2028, USD Million
  • TABLE 199 Asia Pacific Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 200 Asia Pacific Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 201 China Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 202 China Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 203 China Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 204 China Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 205 China Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 206 China Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 207 China Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 208 China Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 209 Japan Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 210 Japan Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 211 Japan Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 212 Japan Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 213 Japan Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 214 Japan Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 215 Japan Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 216 Japan Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 217 India Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 218 India Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 219 India Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 220 India Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 221 India Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 222 India Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 223 India Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 224 India Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 225 South Korea Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 226 South Korea Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 227 South Korea Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 228 South Korea Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 229 South Korea Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 230 South Korea Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 231 South Korea Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 232 South Korea Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 233 Singapore Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 234 Singapore Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 235 Singapore Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 236 Singapore Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 237 Singapore Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 238 Singapore Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 239 Singapore Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 240 Singapore Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 241 Malaysia Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 242 Malaysia Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 243 Malaysia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 244 Malaysia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 245 Malaysia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 246 Malaysia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 247 Malaysia Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 248 Malaysia Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 249 Rest of Asia Pacific Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 250 Rest of Asia Pacific Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 251 Rest of Asia Pacific Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 252 Rest of Asia Pacific Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 253 Rest of Asia Pacific Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 254 Rest of Asia Pacific Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 255 Rest of Asia Pacific Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 256 Rest of Asia Pacific Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 257 LAMEA Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 258 LAMEA Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 259 LAMEA Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 260 LAMEA Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 261 LAMEA Beta-Adrenergic Market by Country, 2018 - 2021, USD Million
  • TABLE 262 LAMEA Beta-Adrenergic Market by Country, 2022 - 2028, USD Million
  • TABLE 263 LAMEA Xanthine Derivatives Market by Country, 2018 - 2021, USD Million
  • TABLE 264 LAMEA Xanthine Derivatives Market by Country, 2022 - 2028, USD Million
  • TABLE 265 LAMEA Anticholinergic Market by Country, 2018 - 2021, USD Million
  • TABLE 266 LAMEA Anticholinergic Market by Country, 2022 - 2028, USD Million
  • TABLE 267 LAMEA Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 268 LAMEA Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 269 LAMEA Nasal (Inhalable) Market by Country, 2018 - 2021, USD Million
  • TABLE 270 LAMEA Nasal (Inhalable) Market by Country, 2022 - 2028, USD Million
  • TABLE 271 LAMEA Oral Market by Country, 2018 - 2021, USD Million
  • TABLE 272 LAMEA Oral Market by Country, 2022 - 2028, USD Million
  • TABLE 273 LAMEA Injectable Market by Country, 2018 - 2021, USD Million
  • TABLE 274 LAMEA Injectable Market by Country, 2022 - 2028, USD Million
  • TABLE 275 LAMEA Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 276 LAMEA Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 277 LAMEA Asthma Market by Country, 2018 - 2021, USD Million
  • TABLE 278 LAMEA Asthma Market by Country, 2022 - 2028, USD Million
  • TABLE 279 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2018 - 2021, USD Million
  • TABLE 280 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country, 2022 - 2028, USD Million
  • TABLE 281 LAMEA Others Market by Country, 2018 - 2021, USD Million
  • TABLE 282 LAMEA Others Market by Country, 2022 - 2028, USD Million
  • TABLE 283 LAMEA Bronchodilators Market by Country, 2018 - 2021, USD Million
  • TABLE 284 LAMEA Bronchodilators Market by Country, 2022 - 2028, USD Million
  • TABLE 285 Brazil Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 286 Brazil Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 287 Brazil Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 288 Brazil Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 289 Brazil Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 290 Brazil Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 291 Brazil Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 292 Brazil Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 293 Argentina Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 294 Argentina Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 295 Argentina Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 296 Argentina Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 297 Argentina Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 298 Argentina Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 299 Argentina Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 300 Argentina Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 301 UAE Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 302 UAE Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 303 UAE Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 304 UAE Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 305 UAE Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 306 UAE Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 307 UAE Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 308 UAE Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 309 Saudi Arabia Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 310 Saudi Arabia Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 311 Saudi Arabia Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 312 Saudi Arabia Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 313 Saudi Arabia Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 314 Saudi Arabia Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 315 Saudi Arabia Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 316 Saudi Arabia Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 317 South Africa Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 318 South Africa Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 319 South Africa Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 320 South Africa Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 321 South Africa Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 322 South Africa Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 323 South Africa Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 324 South Africa Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 325 Nigeria Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 326 Nigeria Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 327 Nigeria Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 328 Nigeria Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 329 Nigeria Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 330 Nigeria Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 331 Nigeria Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 332 Nigeria Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 333 Rest of LAMEA Bronchodilators Market, 2018 - 2021, USD Million
  • TABLE 334 Rest of LAMEA Bronchodilators Market, 2022 - 2028, USD Million
  • TABLE 335 Rest of LAMEA Bronchodilators Market by Drug Class, 2018 - 2021, USD Million
  • TABLE 336 Rest of LAMEA Bronchodilators Market by Drug Class, 2022 - 2028, USD Million
  • TABLE 337 Rest of LAMEA Bronchodilators Market by Route of Administration, 2018 - 2021, USD Million
  • TABLE 338 Rest of LAMEA Bronchodilators Market by Route of Administration, 2022 - 2028, USD Million
  • TABLE 339 Rest of LAMEA Bronchodilators Market by Disease, 2018 - 2021, USD Million
  • TABLE 340 Rest of LAMEA Bronchodilators Market by Disease, 2022 - 2028, USD Million
  • TABLE 341 Key Information - Glenmark Pharmaceuticals Limited
  • TABLE 342 KEY INFORMATION - Merck & Co., Inc.
  • TABLE 343 Key Information - GlaxoSmithKline PLC
  • TABLE 344 KEY INFORMATION - AstraZeneca PLC
  • TABLE 345 Key Information - Teva Pharmaceuticals Industries Ltd.
  • TABLE 346 Key Information - Cipla Limited
  • TABLE 347 key information - Viatris, Inc.
  • TABLE 348 Key Information - Novartis AG
  • TABLE 349 Key Information - Boehringer Ingelheim International GmbH
  • TABLE 350 Key Information - Sun Pharmaceutical Industries Ltd.

List of Figures

  • FIG 1 Methodology for the research
  • FIG 2 Global Bronchodilators Market share by Drug Class, 2021
  • FIG 3 Global Bronchodilators Market share by Drug Class, 2028
  • FIG 4 Global Bronchodilators Market by Drug Class, 2018 - 2028, USD Million
  • FIG 5 Global Bronchodilators Market share by Route of Administration, 2021
  • FIG 6 Global Bronchodilators Market share by Route of Administration, 2028
  • FIG 7 Global Bronchodilators Market by Route of Administration, 2018 - 2028, USD Million
  • FIG 8 Global Bronchodilators Market share by Disease, 2021
  • FIG 9 Global Bronchodilators Market share by Disease, 2028
  • FIG 10 Global Bronchodilators Market by Disease, 2018 - 2028, USD Million
  • FIG 11 Global Bronchodilators Market share by Region, 2021
  • FIG 12 Global Bronchodilators Market share by Region, 2028
  • FIG 13 Global Bronchodilators Market by Region, 2018 - 2028, USD Million
目次

The Global Bronchodilators Market size is expected to reach $27 billion by 2028, rising at a market growth of 3.9% CAGR during the forecast period.

Bronchodilators are drugs that relax the muscles which tighten around the airways. These drugs open airways and allow more air to come and pass through the lungs and decrease mucus from the lungs. Patients suffering from various respiratory disorders take these drugs through nebulizers or inhalers. Also, inhaling bronchodilators have effects on mucociliary clearance too.

Bronchodilators are also utilized to treat obstructive lung diseases by relaxing the muscles in the lungs and widening the airways (bronchi). They also treat chronic obstructive pulmonary diseases (COPD) and asthma. The relaxation of the muscles in the airways due to the bronchodilators, opens them up and the bronchial tube to widen. They come in different types and each works in a slightly different way than the other. They are; beta 2-agonists, anticholinergics and xanthine derivatives (theophylline).

Beta-2 agonists are utilized for both COPD and asthma, but some beta-2 agonists are only recommended for patients with COPD. They are generally inhaled with the help of a small handheld inhaler but are available as syrups or tablets too. In case of sudden or severe symptoms, they can also be injected into the body or nebulized. A nebulizer is a compressor that changes the liquid medication into a fine mist. Beta-2 agonists work by stimulating receptors known as beta-2 receptors in the muscles that are in the airways, which causes them to relax and allow the airways to dilate.

Anticholinergics, also known as antimuscarinics, are majorly used for treating COPD, but in some cases, they can also be used to treat asthma. They are taken with the help of an inhaler, but nebulizing the medication is also available for sudden need. Anticholinergics cause the airway to dilate by blocking the cholinergic nerves. These nerves release a chemical that can force the muscles lining the airways to tighten up. Theophylline is generally taken in capsule or tablet form, but a different version called aminophylline can be given directly into the vein if the symptoms are severe.

COVID-19 Impact Analysis

COVID-19 has impacted the bronchodilators market in the starting phase due to the lockdowns by many nations with the denied COPD and asthma treatment due to the given importance to COVID-19 patients. Because of the halt in the supply chain, there was a shortage of bronchodilator medications. Many bronchodilators manufacturing companies were forced to stop their production due to the pandemic and labor shortage. Furthermore, business operations were halted due to the new government regulations, which directly influenced the companies' revenue in the bronchodilators market.

Market Growth Factor

Increasing air pollution across the globe

Motor vehicles, household combustion, forest fires, and industrial facilities are familiar air pollution sources. Pollutants of primary public health concern contain particulate matter, carbon monoxide, ozone, sulfur dioxide, and nitrogen. Indoor and outdoor air pollution cause respiratory and other diseases and are significant factors for mortality and morbidity. According to World Health Organization, almost all of the world's population breathes air that exceeds WHO guideline limits and has high levels of pollutants. Out of that, low and middle-income countries are suffering from the highest exposures.

Surging number of geriatric populations

According to WHO, one in every six people in the world will be aged 60 years or over by 2030. The share of the world's population aged 60 years and above will rise from 1 billion in 2020 to 1.4 billion. The world's population of people aged 60 years and older will double to around 2.1 billion, and the 80 years old will triple to 426 million between 2020 and 2050. While this shift in the distribution of a country's population towards the older ages, called population aging, has already started in high-income nations, it is now experiencing the most significant change in low- and middle-income countries. By 2050, two-thirds of the world's population will be over 60 years old and in low- or middle-income countries.

Market Restraining Factor

High cost of imaging equipment

A chest X-ray can aid in assisting the diagnosis of many lung diseases and rule out other causes of shortness of breath. Various hospitals in developing nations cannot invest in diagnostic imaging equipment due to high costs and financial restrictions. Many hospitals that cannot buy new cutting-edge imaging systems instead opt to utilize rebuilt imaging systems because of the high demand for diagnostics procedures, especially in low-income countries.

Drug Class Outlook

Based on drug class, the bronchodilators market is segmented into beta-adrenergic, xanthine derivatives and anticholinergic. The anticholinergic segment acquired a promising growth rate in the bronchodilators market in 2021. This is due to anticholinergics' availability in short- and long-acting formulations. These drugs prevent the parasympathetic nerve reflexes from airways constriction, which allows the airways to remain open.

Route of Administration Outlook

On the basis of route of administration, the bronchodilators market is divided into oral, nasal (inhalable) and injectable. The oral segment procured a prominent revenue share in the bronchodilator market in 2021. This is because many patients and clinicians prefer to avoid the adverse effects of injectables administration. Also, they are less costly than many generic substitutes and have many advantages like non-invasiveness, the convenience of drug administration, and patient compliance.

Disease Outlook

By disease, the bronchodilators market is classified into asthma, chronic obstructive pulmonary disease (COPD) and others. The asthma segment witnessed the largest revenue share in the bronchodilator market in 2021. This is due to the rising prevalence of asthma among the population. In addition, there is a robust research and development pipeline with many mid or late-stage development organizations.

Regional Outlook

Region-wise, the bronchodilators market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the bronchodilator market in 2021. The growth is due to the increasing demand for fast-acting and high-efficiency drugs. The surging COPD cases are due to air pollution, dust, working with chemicals, a history of childhood lung infection, and second-hand smoke. Also, there is a large number of smokers who are suffering from a smoke-related disease. The air pollution, high smoker count, and the rising number of old adults are expected to boost the bronchodilators market growth in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.

Scope of the Study

Market Segments covered in the Report:

By Drug Class

  • Beta-Adrenergic
  • Xanthine Derivatives
  • Anticholinergic

By Route of Administration

  • Nasal (Inhalable)
  • Oral
  • Injectable

By Disease

  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
  • LAMEA
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Glenmark Pharmaceuticals Limited
  • Merck & Co., Inc.
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Teva Pharmaceuticals Industries Ltd.
  • Cipla Limited
  • Viatris, Inc.
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Sun Pharmaceutical Industries Ltd.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Global Bronchodilators Market, by Drug Class
    • 1.4.2 Global Bronchodilators Market, by Route of Administration
    • 1.4.3 Global Bronchodilators Market, by Disease
    • 1.4.4 Global Bronchodilators Market, by Geography
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
    • 2.1.1 Overview
      • 2.1.1.1 Market composition and Scenario
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Global Bronchodilators Market by Drug Class

  • 3.1 Global Beta-Adrenergic Market by Region
  • 3.2 Global Xanthine Derivatives Market by Region
  • 3.3 Global Anticholinergic Market by Region

Chapter 4. Global Bronchodilators Market by Route of Administration

  • 4.1 Global Nasal (Inhalable) Market by Region
  • 4.2 Global Oral Market by Region
  • 4.3 Global Injectable Market by Region

Chapter 5. Global Bronchodilators Market by Disease

  • 5.1 Global Asthma Market by Region
  • 5.2 Global Chronic Obstructive Pulmonary Disease (COPD) Market by Region
  • 5.3 Global Others Market by Region

Chapter 6. Global Bronchodilators Market by Region

  • 6.1 North America Bronchodilators Market
    • 6.1.1 North America Bronchodilators Market by Drug Class
      • 6.1.1.1 North America Beta-Adrenergic Market by Country
      • 6.1.1.2 North America Xanthine Derivatives Market by Country
      • 6.1.1.3 North America Anticholinergic Market by Country
    • 6.1.2 North America Bronchodilators Market by Route of Administration
      • 6.1.2.1 North America Nasal (Inhalable) Market by Country
      • 6.1.2.2 North America Oral Market by Country
      • 6.1.2.3 North America Injectable Market by Country
    • 6.1.3 North America Bronchodilators Market by Disease
      • 6.1.3.1 North America Asthma Market by Country
      • 6.1.3.2 North America Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.1.3.3 North America Others Market by Country
    • 6.1.4 North America Bronchodilators Market by Country
      • 6.1.4.1 US Bronchodilators Market
        • 6.1.4.1.1 US Bronchodilators Market by Drug Class
        • 6.1.4.1.2 US Bronchodilators Market by Route of Administration
        • 6.1.4.1.3 US Bronchodilators Market by Disease
      • 6.1.4.2 Canada Bronchodilators Market
        • 6.1.4.2.1 Canada Bronchodilators Market by Drug Class
        • 6.1.4.2.2 Canada Bronchodilators Market by Route of Administration
        • 6.1.4.2.3 Canada Bronchodilators Market by Disease
      • 6.1.4.3 Mexico Bronchodilators Market
        • 6.1.4.3.1 Mexico Bronchodilators Market by Drug Class
        • 6.1.4.3.2 Mexico Bronchodilators Market by Route of Administration
        • 6.1.4.3.3 Mexico Bronchodilators Market by Disease
      • 6.1.4.4 Rest of North America Bronchodilators Market
        • 6.1.4.4.1 Rest of North America Bronchodilators Market by Drug Class
        • 6.1.4.4.2 Rest of North America Bronchodilators Market by Route of Administration
        • 6.1.4.4.3 Rest of North America Bronchodilators Market by Disease
  • 6.2 Europe Bronchodilators Market
    • 6.2.1 Europe Bronchodilators Market by Drug Class
      • 6.2.1.1 Europe Beta-Adrenergic Market by Country
      • 6.2.1.2 Europe Xanthine Derivatives Market by Country
      • 6.2.1.3 Europe Anticholinergic Market by Country
    • 6.2.2 Europe Bronchodilators Market by Route of Administration
      • 6.2.2.1 Europe Nasal (Inhalable) Market by Country
      • 6.2.2.2 Europe Oral Market by Country
      • 6.2.2.3 Europe Injectable Market by Country
    • 6.2.3 Europe Bronchodilators Market by Disease
      • 6.2.3.1 Europe Asthma Market by Country
      • 6.2.3.2 Europe Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.2.3.3 Europe Others Market by Country
    • 6.2.4 Europe Bronchodilators Market by Country
      • 6.2.4.1 Germany Bronchodilators Market
        • 6.2.4.1.1 Germany Bronchodilators Market by Drug Class
        • 6.2.4.1.2 Germany Bronchodilators Market by Route of Administration
        • 6.2.4.1.3 Germany Bronchodilators Market by Disease
      • 6.2.4.2 UK Bronchodilators Market
        • 6.2.4.2.1 UK Bronchodilators Market by Drug Class
        • 6.2.4.2.2 UK Bronchodilators Market by Route of Administration
        • 6.2.4.2.3 UK Bronchodilators Market by Disease
      • 6.2.4.3 France Bronchodilators Market
        • 6.2.4.3.1 France Bronchodilators Market by Drug Class
        • 6.2.4.3.2 France Bronchodilators Market by Route of Administration
        • 6.2.4.3.3 France Bronchodilators Market by Disease
      • 6.2.4.4 Russia Bronchodilators Market
        • 6.2.4.4.1 Russia Bronchodilators Market by Drug Class
        • 6.2.4.4.2 Russia Bronchodilators Market by Route of Administration
        • 6.2.4.4.3 Russia Bronchodilators Market by Disease
      • 6.2.4.5 Spain Bronchodilators Market
        • 6.2.4.5.1 Spain Bronchodilators Market by Drug Class
        • 6.2.4.5.2 Spain Bronchodilators Market by Route of Administration
        • 6.2.4.5.3 Spain Bronchodilators Market by Disease
      • 6.2.4.6 Italy Bronchodilators Market
        • 6.2.4.6.1 Italy Bronchodilators Market by Drug Class
        • 6.2.4.6.2 Italy Bronchodilators Market by Route of Administration
        • 6.2.4.6.3 Italy Bronchodilators Market by Disease
      • 6.2.4.7 Rest of Europe Bronchodilators Market
        • 6.2.4.7.1 Rest of Europe Bronchodilators Market by Drug Class
        • 6.2.4.7.2 Rest of Europe Bronchodilators Market by Route of Administration
        • 6.2.4.7.3 Rest of Europe Bronchodilators Market by Disease
  • 6.3 Asia Pacific Bronchodilators Market
    • 6.3.1 Asia Pacific Bronchodilators Market by Drug Class
      • 6.3.1.1 Asia Pacific Beta-Adrenergic Market by Country
      • 6.3.1.2 Asia Pacific Xanthine Derivatives Market by Country
      • 6.3.1.3 Asia Pacific Anticholinergic Market by Country
    • 6.3.2 Asia Pacific Bronchodilators Market by Route of Administration
      • 6.3.2.1 Asia Pacific Nasal (Inhalable) Market by Country
      • 6.3.2.2 Asia Pacific Oral Market by Country
      • 6.3.2.3 Asia Pacific Injectable Market by Country
    • 6.3.3 Asia Pacific Bronchodilators Market by Disease
      • 6.3.3.1 Asia Pacific Asthma Market by Country
      • 6.3.3.2 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.3.3.3 Asia Pacific Others Market by Country
    • 6.3.4 Asia Pacific Bronchodilators Market by Country
      • 6.3.4.1 China Bronchodilators Market
        • 6.3.4.1.1 China Bronchodilators Market by Drug Class
        • 6.3.4.1.2 China Bronchodilators Market by Route of Administration
        • 6.3.4.1.3 China Bronchodilators Market by Disease
      • 6.3.4.2 Japan Bronchodilators Market
        • 6.3.4.2.1 Japan Bronchodilators Market by Drug Class
        • 6.3.4.2.2 Japan Bronchodilators Market by Route of Administration
        • 6.3.4.2.3 Japan Bronchodilators Market by Disease
      • 6.3.4.3 India Bronchodilators Market
        • 6.3.4.3.1 India Bronchodilators Market by Drug Class
        • 6.3.4.3.2 India Bronchodilators Market by Route of Administration
        • 6.3.4.3.3 India Bronchodilators Market by Disease
      • 6.3.4.4 South Korea Bronchodilators Market
        • 6.3.4.4.1 South Korea Bronchodilators Market by Drug Class
        • 6.3.4.4.2 South Korea Bronchodilators Market by Route of Administration
        • 6.3.4.4.3 South Korea Bronchodilators Market by Disease
      • 6.3.4.5 Singapore Bronchodilators Market
        • 6.3.4.5.1 Singapore Bronchodilators Market by Drug Class
        • 6.3.4.5.2 Singapore Bronchodilators Market by Route of Administration
        • 6.3.4.5.3 Singapore Bronchodilators Market by Disease
      • 6.3.4.6 Malaysia Bronchodilators Market
        • 6.3.4.6.1 Malaysia Bronchodilators Market by Drug Class
        • 6.3.4.6.2 Malaysia Bronchodilators Market by Route of Administration
        • 6.3.4.6.3 Malaysia Bronchodilators Market by Disease
      • 6.3.4.7 Rest of Asia Pacific Bronchodilators Market
        • 6.3.4.7.1 Rest of Asia Pacific Bronchodilators Market by Drug Class
        • 6.3.4.7.2 Rest of Asia Pacific Bronchodilators Market by Route of Administration
        • 6.3.4.7.3 Rest of Asia Pacific Bronchodilators Market by Disease
  • 6.4 LAMEA Bronchodilators Market
    • 6.4.1 LAMEA Bronchodilators Market by Drug Class
      • 6.4.1.1 LAMEA Beta-Adrenergic Market by Country
      • 6.4.1.2 LAMEA Xanthine Derivatives Market by Country
      • 6.4.1.3 LAMEA Anticholinergic Market by Country
    • 6.4.2 LAMEA Bronchodilators Market by Route of Administration
      • 6.4.2.1 LAMEA Nasal (Inhalable) Market by Country
      • 6.4.2.2 LAMEA Oral Market by Country
      • 6.4.2.3 LAMEA Injectable Market by Country
    • 6.4.3 LAMEA Bronchodilators Market by Disease
      • 6.4.3.1 LAMEA Asthma Market by Country
      • 6.4.3.2 LAMEA Chronic Obstructive Pulmonary Disease (COPD) Market by Country
      • 6.4.3.3 LAMEA Others Market by Country
    • 6.4.4 LAMEA Bronchodilators Market by Country
      • 6.4.4.1 Brazil Bronchodilators Market
        • 6.4.4.1.1 Brazil Bronchodilators Market by Drug Class
        • 6.4.4.1.2 Brazil Bronchodilators Market by Route of Administration
        • 6.4.4.1.3 Brazil Bronchodilators Market by Disease
      • 6.4.4.2 Argentina Bronchodilators Market
        • 6.4.4.2.1 Argentina Bronchodilators Market by Drug Class
        • 6.4.4.2.2 Argentina Bronchodilators Market by Route of Administration
        • 6.4.4.2.3 Argentina Bronchodilators Market by Disease
      • 6.4.4.3 UAE Bronchodilators Market
        • 6.4.4.3.1 UAE Bronchodilators Market by Drug Class
        • 6.4.4.3.2 UAE Bronchodilators Market by Route of Administration
        • 6.4.4.3.3 UAE Bronchodilators Market by Disease
      • 6.4.4.4 Saudi Arabia Bronchodilators Market
        • 6.4.4.4.1 Saudi Arabia Bronchodilators Market by Drug Class
        • 6.4.4.4.2 Saudi Arabia Bronchodilators Market by Route of Administration
        • 6.4.4.4.3 Saudi Arabia Bronchodilators Market by Disease
      • 6.4.4.5 South Africa Bronchodilators Market
        • 6.4.4.5.1 South Africa Bronchodilators Market by Drug Class
        • 6.4.4.5.2 South Africa Bronchodilators Market by Route of Administration
        • 6.4.4.5.3 South Africa Bronchodilators Market by Disease
      • 6.4.4.6 Nigeria Bronchodilators Market
        • 6.4.4.6.1 Nigeria Bronchodilators Market by Drug Class
        • 6.4.4.6.2 Nigeria Bronchodilators Market by Route of Administration
        • 6.4.4.6.3 Nigeria Bronchodilators Market by Disease
      • 6.4.4.7 Rest of LAMEA Bronchodilators Market
        • 6.4.4.7.1 Rest of LAMEA Bronchodilators Market by Drug Class
        • 6.4.4.7.2 Rest of LAMEA Bronchodilators Market by Route of Administration
        • 6.4.4.7.3 Rest of LAMEA Bronchodilators Market by Disease

Chapter 7. Company Profiles

  • 7.1 Glenmark Pharmaceuticals Limited
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Research & Development Expenses
    • 7.1.4 Recent strategies and developments:
      • 7.1.4.1 Product Launches and Product Expansions:
  • 7.2 Merck & Co., Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Segmental and Regional Analysis
    • 7.2.4 Research & Development Expenses
  • 7.3 GlaxoSmithKline PLC
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expense
  • 7.4 AstraZeneca PLC
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Regional Analysis
    • 7.4.4 Research & Development Expenses
  • 7.5 Teva Pharmaceutical Industries Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Regional Analysis
    • 7.5.4 Research & Development Expenses
  • 7.6 Cipla Limited
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Regional Analysis
    • 7.6.4 Research & Development Expense
  • 7.7 Viatris, Inc. (Mylan N.V.)
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Boehringer Ingelheim International Gmbh
    • 7.9.1 Company Overview
    • 7.9.2 Financial Analysis
    • 7.9.3 Regional & Segmental Analysis
    • 7.9.4 Research & Development Expenses
  • 7.10. Sun Pharmaceutical Industries Ltd.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Regional & Segmental Analysis
    • 7.10.4 Research & Development Expenses